Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway

Oncogene volume 22, pages 3353–3360 (2003)Cite this article

Abstract

In the MCF-7 breast cancer cell line, insulin-like growth factors (IGFs) are known to elicit antiproliferative actions via the insulin receptor substrate-1 (IRS-1)/PI 3-kinase/AKT pathway. All-trans retinoic acid (RA) is a potent inhibitor of MCF-7 cell proliferation, but the mechanism by which growth regulation is achieved remains unclear. We investigated the effects of RA on the regulation of the IGF-IR and its key signaling elements: IRS-1, IRS-2, and SHC. Treatment of MCF-7 cells with RA caused a significant reduction in IRS-1 protein and tyrosine phosphorylation levels at a concentration and time consistent with RA-mediated growth inhibition. IRS-1 regulation is selective, as RA did not influence IRS-2 or SHC levels. Downstream signaling events were also selectively reduced, as RA abrogated IGF-I-stimulated AKT activation but did not alter erk1/2 activation. To confirm the importance of IRS-1 regulation by RA, we examined the response to RA in MCF-7 cells overexpressing IGF-IR and IRS-1. RA resistance was observed in MCF-7 cells overexpressing IRS-1 but not IGF-IR. This suggests that RA-mediated growth inhibition requires the selective downregulation of IRS-1 and AKT. Therapeutic agents targeting the IRS-1/PI 3-kinase/AKT pathway may enhance the cytostatic effects of RA in breast cancer, since overexpression of IRS-1 and AKT have been reported in primary breast tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Agadir A, Chen G, Bost F, Li Y, Mercola D and Zhang X . (1999). J. Biol. Chem., 274, 29779–29785.

  • Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings B . (1996). EMBO J., 15, 6541–6551.

  • Allen LF, Lenehan PF, Eiseman IA, Elliott WL and Fry DW . (2002). Semin. Oncol., 29, 11–21.

  • Ando S, Panno ML, Salerno M, Sisci D, Mauro L, Lanzino M and Surmacz E . (1998). Biochem. Biophys. Res. Commun., 253, 315–319.

  • Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB and Sporn MB . (1994). Cancer Res., 54, 4614–4617.

  • Beitner-Johnson D and LeRoith D . (1995). J. Biol. Chem., 270, 5187–5190.

  • Blakesley VA, Kalebic T, Helman LJ, Stannard B, Faria TN, Roberts Jr CT and LeRoith D . (1996). Endocrinology, 137, 410–417.

  • Chang Q, Li Y, White MF, Fletcher JA and Xiao S . (2002). Cancer Res., 62, 6035–6038.

  • Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME and Rosen N . (1990). Cancer Res., 50, 48–53.

  • DeLuca ML . (1991). FASEB J., 5, 2924–2933.

  • de Vente JE, Carey JO, Byrant WO, Pettit GJ and Ways DK . (1996). J. Biol. Chem., 271, 32276–32280.

  • Dey BR, Frick K, Lopaczynski W, Nissley SP and Furlanetto RW . (1996). Mol. Endocrinol., 10, 631–641.

  • Dow R, Hendley J, Pirkmaier A, Musgrove EA and Germain D . (2001). J. Biol. Chem., 276, 45945–45951.

  • Downward J . (1995). Nature, 376, 553–554.

  • Dragnev KH, Rigas JR and Dmitrovsky E . (2000). Oncologist, 5, 361–368.

  • Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH and Sussenbach JS . (1997). J. Biol. Chem., 272, 31163–31171.

  • Fontana JA, Burrows-Mezu A, Clemmons DR and LeRoith D . (1991). Endocrinology, 128, 1115–1152.

  • Franke T, Yang S, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR and Tsichilis PN . (1995). Cell, 81, 727–736.

  • Gianni M, Kopf E, Bastien J, Oulad-Abdelghani M, Garattini E, Chambon P and Rochette-Egly C . (2002). J. Biol. Chem., 277, 24859–24862.

  • Goalstone ML, Leitner JW, Berhanu P, Sharma PM, Olefsky JM and Draznin B . (2001). J. Biol. Chem., 276, 12805–12812.

  • Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT and Benbrook DM . (2001). J. Natl. Cancer Inst., 93, 516–525.

  • Guvakova MA and Surmacz E . (1997). Exp. Cell Res., 231, 149–162.

  • Ishibashi KI, Imamura T, Sharma PM, Huang J, Ugi S and Olefsky JM . (2001). J. Clin. Invest., 107, 1193–1202.

  • Jackson JG, White MF and Yee D . (1998). J. Biol. Chem., 273, 9994–10003.

  • Jackson JG, Zhang X, Yoneda T and Yee D . (2001). Oncogene, 20, 7318–7325.

  • Jones PF, Jakubowitz T, Pitossi FJ, Maurer F and Hemmings BA . (1991). Nature, 376, 599–602.

  • Kulik G, Klippel A and Weber MJ . (1997). Mol. Cell. Biol., 17, 1595–1606.

  • Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK and Yee D . (1999). Mol. Endocrinol., 13, 787–796.

  • Lee J and Pilch PF . (1994). Am. J. Physiol., 266, C319–C334.

  • Li Q and Zhu GD . (2002). Curr Top Med. Chem., 2, 939–971.

  • Li XS, Chen JC, Sheikh MS, Shao ZM and Fontana JA . (1994). Exp. Cell Res., 211, 68–73.

  • Li Y and Sarkar FH . (2002). Clin. Cancer Res., 8, 2369–2377.

  • Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC and Zhang X . (1996). Mol. Cell. Biol., 16, 1138–1149.

  • Mauro L, Sisci D, Bartucci M, Salerno M, Kim J, Tam T, Guvakova MA, Ando S and Surmacz E . (1999). Exp. Cell Res., 252, 439–448.

  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG and Anderson KC . (2002). Oncogene, 21, 5673–5683.

  • Moon RC and Constantinou AI . (1997). Breast Cancer Res. Treatment, 46, 181–189.

  • Myers Jr MG, Wang LM, Sun XJ, Zhang Y, Yenush L, Schlessinger J, Pierce JH and White MF . (1994). Mol. Cell. Biol., 14, 3577–3587.

  • Nicholson KM and Anderson NG . (2002). Cell. Signal., 14, 381–395.

  • Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA and Surmacz E . (1997). Int. J. Cancer, 72, 828–834.

  • O'Connor R, Fennelly C and Krause D . (2000). Biochem. Soc. Trans., 28, 47–51.

  • Pollak, M . (2000). Eur. J. Cancer, 36, 1224–1228.

  • Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng CN, Lee AV and Yee D . (1997). Clin. Cancer Res., 3, 103–109.

  • Rosenauer A, Nervi C, Davison K, Lamph WW, Mader S and Miller Jr WH . (1998). Cancer Res., 58, 5110–5116.

  • Rozen F and Pollak M . (1999). Int. J. Oncol., 15, 589–594.

  • Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J and Miller Jr WH . (1994). Cancer Res., 54, 6549–6556.

  • Sachdev D and Yee D . (2001). Endocr. Relat. Cancer, 8, 197–209.

  • Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S and Surmacz E . (1999). Int. J. Cancer, 81, 299–304.

  • Shang Y, Baumrucker CR and Green MH . (1999). J. Biol. Chem., 274, 18005–18010.

  • Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers Jr MJ, Backer JM, Ullrich A and White MF . (1993). EMBO J., 12, 1929–1936.

  • Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ and Dmitrovsky E . (1999). J. Biol. Chem., 274, 22013–22018.

  • Sporn MB, Roberts AB and Goodman DS . (1994). The Retinoids: Biology, Chemistry and Medicine. Raven Press: New York, pp. 573–595.

    Google Scholar 

  • Strange R, Metcalfe T, Thackray L and Dang M . (2001). Microsc. Res. Tech., 52, 171–181.

  • Sueoka N, Lee HY, Walsh GL, Hong WK and Kurie JM . (1999). Cancer Res., 59, 3838–3844.

  • Sun XJ, Goldberg JL, Qiao LY and Mitchell JJ . (1999). Diabetes, 48, 1359–1364.

  • Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ and White MF . (1991). Nature, 352, 73–77.

  • Sun XJ, Wang LM, Zhang Y, Yenush L, Myers Jr MG, Glasheen E, Lane WS, Pierce JH and White MF . (1995). Nature, 377, 173–177.

  • Surmacz E and Burgaud JL . (1995). Clin. Cancer Res., 1, 1429–1436.

  • Tanaka T, Rodriquez de la Concepcion ML and De Luca LM . (2001). Biochem. Pharmacol., 61, 1347–1355.

  • Taouis M, Dupont J, Gillet A, Derouet M and Simon J . (1998). Mol. Cell. Endocrinol., 137, 177–186.

  • Tari AM, Lim SJ, Hung MC, Esteva FJ and Lopez-Berestein G . (2002). Oncogene, 21, 5224–5232.

  • Torrisi R, Decensi A, Formelli F, Camerini T and De Palo G . (2001). Drugs, 61, 909–918.

  • Veronesi U, De Palo G, Marubini E et al. (1999). J. Natl. Cancer Inst., 91, 1847–1856.

  • Wang Q, Yang W, Uytingco MS, Christakos S and Wieder R . (2000). Cancer Res., 60, 2040–2048.

  • Waters SB, Yamauchi K and Pessin JE . (1993). J. Biol. Chem., 268, 22231–22234.

  • White MF . (1997). Diabetologia, 40, S2–S17.

  • White MF and Kahn CR . (1994). J. Biol. Chem., 269, 1–4.

  • Xie SP, James SY and Colston KW . (1997). J. Endocrinol., 154, 495–504.

  • Xie SP, Pirianov G and Colston KW . (1999). Eur. J. Cancer, 35, 1717–1723.

  • Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL . (2002). Cancer Res., 62, 4132–4141.

  • Yoshida H, Kitamura K., Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R and Naoe T . (1996). Cancer Res., 56, 2945–2948.

  • Zhande R, Mitchell JJ, Wu J and Sun XJ . (2002). Mol. Cell. Biol., 22, 1016–1026.

  • Zhang H, Hoff H and Sell C . (2000). J. Biol. Chem., 275, 22558–22562.

  • Zhou Q, Stetler-Stevenson M and Steeg PS . (1997). Oncogene, 15, 107–115.

  • Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S and De Luca LM . (1997). Exp. Cell Res., 234, 293–299.

Download references

Acknowledgements

We thank Dr Ewa Surmacz for helpful discussion and for providing the MCF-7 cells stably transfected with various IGF signaling components. This work was supported by a predoctoral fellowship award from the US Army Medical Research and Material Command Breast Cancer Research Program (award number DAMD1701-1-0320 to SV del Rincón) and a grant from the Canadian Breast Cancer Research Initiative. Wilson H Miller Jr is an Investigator of the Canadian Institutes of Health Research.

Author information

Authors and Affiliations

  1. Departments of Oncology and Medicine, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, Quebec, Canada

    Sonia V del Rincón, Caroline Rousseau, Ratna Samanta & Wilson H Miller Jr

Authors
  1. Sonia V del Rincón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ratna Samanta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wilson H Miller Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilson H Miller Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

del Rincón, S., Rousseau, C., Samanta, R. et al. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway. Oncogene 22, 3353–3360 (2003). https://doi.org/10.1038/sj.onc.1206485

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206485

Keywords

This article is cited by

Search

Advanced search

Quick links